[Webinar] Improve Oncology Clinical Trial Readiness for Faster Proof-of-Concept

June 11, 2026
10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central)
Europe, US, APAC

Watch On-Demand

About This Webinar

Emerald Clinical presents “Improve Oncology Clinical Trial Readiness for Faster Proof-of-Concept,” featuring experts Luke Gill and Dr. Yong Wang. 

This webinar explores how adaptive strategies, specifically Bayesian designs, master protocols, and Real-World Evidence (RWE) can overcome rising costs and low success rates. Learn how these data-driven approaches accelerate PoC, de-risk development, and enable earlier integration of China into global clinical pathways to compress timelines and improve regulatory success.

Accelerating Proof-of-Concept (PoC): Adopt adaptive, data-driven strategies to achieve faster and more confident go/no-go decisions, overcoming the hurdles of rising costs and extended timelines.

Precision Dose Finding with Bayesian Designs: Use Bayesian model-assisted designs (like BOIN) to continuously incorporate data, reducing patient exposure to toxic doses while more accurately identifying the optimal biological dose.

Operational Efficiency via Master Protocols: Implement basket, umbrella, and platform trials to evaluate multiple therapies under one infrastructure, significantly reducing redundancy and shortening global development cycles. 

Strategic Integration of China: Structure trials to include China from the outset—using harmonized protocols and regional modules—to eliminate the need for late-stage bridging studies and access critical patient populations sooner. 

De-Risking with Real-World Evidence (RWE): Leverage high-quality RWE to support hybrid control arms, contextualize results, and inform endpoint selection, strengthening both regulatory submissions and payer discussions.